Bipolar Disorder, Psychotic Disorders, Schizophrenia
Conditions
Keywords
schizoaffective disorder, schizophreniform disorder, bipolar I disorder
Brief summary
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity. In this study, the Anti-obesity Agent is being tested to see if it can treat weight gain that may be associated with taking olanzapine. The purposes of this study are to determine the safety of olanzapine when given in combination with the Anti-obesity Agent and any side effects that might be associated with it and whether weight-gain agent can help treat weight gain that may be associated with taking olanzapine.
Interventions
DRUGSibutramine
Sponsors
Eli Lilly and Company
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Eligibility Criteria: * You must be between the ages of 18 and 65. If you have reached your 66th birthday, you will not be able to participate. * You must have been diagnosed with schizophrenia, schizoaffective disorder, schizophreniform disorder, or bipolar I disorder and be taking olanzapine. * You must be able to visit the doctor's office as scheduled for the next 4 months.
Exclusion criteria
* You have a history of an illness that would cause weight loss or gain in the near future. * You have taken remoxipride within the past 6 months. * You are allergic to olanzapine or Anti-obesity Agent. * You have uncontrolled high blood pressure, congestive heart failure, or have had a stroke. * You have a serious medical illness, such as heart, liver, or kidney disease. * You are pregnant or breast feeding.
Countries
United States
Outcome results
None listed